agent

(redirected from angiogenic gene therapy)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Wikipedia.

agent

a person representing a business concern, esp a travelling salesman

Agent

 

in Soviet civil law, a party in a contract of agency. The agent’s duties include the performance of specified legal acts, for example, contracts of sale and management of property, in the name of and on the account of a principal party. The agent may be a legally competent (sui juris) citizen or a legal person (if this is allowed by the latter’s charter or statute). The actions performed by the agent directly generate, change, or extinguish rights and obligations of the principal.

The agent is bound to perform the agency in exact conformity with the principal’s instructions, carry out the agency personally, although in instances provided for by law the responsibilities may be transferred to another person (art. 68 of the RSFSR Civil Code), inform the principal upon demand of progress in performing the agency, submit a report on performance of the agency, and transfer to the principal any property obtained in connection with performance of the agency.

agent

One who is empowered to enter into binding transactions on behalf of another (usually called the principal).

agent

(networking)
In the client-server model, the part of the system that performs information preparation and exchange on behalf of a client or server. Especially in the phrase "intelligent agent" it implies some kind of automatic process which can communicate with other agents to perform some collective task on behalf of one or more humans.

agent

A software routine that waits in the background and performs an action when a specified event occurs. For example, agents could transmit a summary file on the first day of the month or monitor incoming data and alert the user when a certain transaction has arrived. Agents are also called "intelligent agents," "personal agents" and "bots." See mobile agent, bot and workflow.
References in periodicals archive ?
The Generx[Ad5FGF-4] angiogenic gene therapy product candidates are comprised of three key elements that include (1) a myocardial delivery vector; (2) a therapeutic transgene and (3) proprietary methods of gene therapy.
After long-term follow-up, the patients who received angiogenic gene therapy appear to have improved outcomes.
Cardium's therapeutic approach to the treatment of heart disease has been the focus of the most widely-conducted clinical studies for Angiogenic Gene Therapy (AGENT 1 through AGENT 4), which to date have involved 663 patients and more than one hundred United States, European and other medical centers.
Research indicates that the Generx angiogenic gene therapy product candidate has the capacity to enlarge pre-existing collateral arterioles (arteriogenesis) and to form new capillary vessels (angiogenesis) when driven by cardiac hemodynamic-impairment and ischemic stimulus.
The addition of this new gene broadens our portfolio of therapeutic genes and expands the range of commercial opportunities for Collateral in the field of cardiovascular angiogenic gene therapy," said Christopher J.
For example, Schering recently spent over $200 million to acquire Collateral Therapeutics, even though Collateral's angiogenic gene therapy actually failed in its Phase II trials.
The strategic collaboration with Shanxi Taxus is another important step forward to further support our plan to clinical develop and process engineer Cardium's Generx product candidate to be the first universally affordable, easy use and accessible angiogenic gene therapy for patients with Cardiac Microvascular insufficiency potentially for millions with heart disease on a worldwide basis.
San Diego, CA; 858-794-3420) announced the issuance of United States Patent 6,174,871 entitled "Gene Therapies for Enhancing Cardiac Function," which is directed to angiogenic gene therapy methods for treating heart disease.